Toshiba launches Asteion
Toshiba America Medical Systems this month formally introduced Asteion, its latest line of subsecond CT systems. Cleared by the Food and Drug Administration last November (SCAN 11/25/98), Toshiba’s Asteion VR and Asteion VI scanners feature a
Toshiba America Medical Systems this month formally introduced Asteion, its latest line of subsecond CT systems. Cleared by the Food and Drug Administration last November (SCAN 11/25/98), Toshibas Asteion VR and Asteion VI scanners feature a 0.75-second rotation speed and solid-state detectors, with partial reconstruction times as short as half a second using Toshibas image processing algorithms.
The units come equipped with the Tustin, CA-based companys HeliCool x-ray tubes, rated at 4 MHU, and include graphic user interfaces and high-speed power image processors from Silicon Graphics. The scanners support Toshibas Aspire Continuous Imaging real-time scanning protocol. In the future, the Asteion line may be upgraded to Toshibas multislice technology, which will augment possible applications to include advanced CT-angio and cardiac studies, according to Toshiba.
The Asteion line expands Toshibas product offerings, enabling the company to provide both subsecond and multislice scanning at new price points. With the introduction last September of its Aquilion unit, a 0.5-second scanner, Toshiba established a platform for a multislice option to be introduced later this year (SCAN 3/3/99 and 9/16/98). But the Asteion scanners could bridge the gap between conventional single-slice scanners and Aquilion: Although Toshiba did not release a price tag for Asteion, the scanner will likely sell for less than Aquilion.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
